Clinical Trial: A Prospective, Exploratory Study of Lurbinectedin combined with Atezolizumab with or without Anlotinib as Second-line Therapy for Extensive-Stage Small Cell Lung Cancer (China)

China, Sept. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Exploratory Study of Lurbinectedin combined with Atezolizumab with or without Anlotinib as Second-line Therapy for Extensive-Stage Small Cell Lung Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132081

Registration Time: 2026/09/09

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital,Sun Yat-sen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340867

Published by HT Digital Content Services with permission from Health Daily Digest....